Showing results (841-850 of 3,376) with videos related to

Sort By:
Pageof 338
The Lancet. Oncology|August 24, 2026
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trialZhengbo Song, Liming Zhu, Ying Liu, et al.
The Lancet. Oncology|September 15, 2026
Burden of cancer in Africa, 1990-2023: a systematic analysis from the Global Burden of Disease Study 2023
The Lancet. Oncology|September 28, 2026
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trialGuang-Yi Sun, Si-Ye Chen, Yu Tang, et al.
The Lancet. Oncology|September 29, 2026
Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of CancerIan F Tannock, Michael Brundage, Christopher M Booth, et al.
The Lancet. Oncology|September 25, 2026
Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology CommissionRaffaella Casolino, Joaquin Mateo, Elisabeth G E de Vries, et al.
The Lancet. Oncology|October 23, 2026
Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (MASTERPLAN): an open-label, phase 2, multicentre, randomised trial of the Australasian Gastro-Intestinal Trials GroupAndrew Oar, Andrew Kneebone, Katrin M Sjoquist, et al.
The Lancet. Oncology|October 26, 2026
Development of the Children's Oncology Group long-term follow-up guideline for cancer genetics evaluation in childhood cancer survivorsSanyukta K Janardan, Anna Devine, LilyAnne M Grieve, et al.
The Lancet. Oncology|October 28, 2026
Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profilingSteven M Yip, A Douglas Laird, Neeraj Agarwal, et al.
The Lancet. Oncology|November 4, 2026
Survival in patients with renal cell carcinoma and brain metastases: an update of the Renal Graded Prognostic AssessmentPaul W Sperduto, Fasila Johri, Hany Soliman, et al.
The Lancet. Oncology|November 4, 2026
Cancer in the Commonwealth: a Lancet Oncology CommissionRifat Atun, Bhawna Sirohi, David Jaffray, et al.
Pageof 338